Schering Plans For Possible Clarinex Switch By Readying OTC Division
This article was originally published in The Tan Sheet
Executive Summary
Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay
You may also be interested in...
Claritin Hives Relief Approval Could Close Out Rx Product Line
Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19
Schering Cost Cuts Run Deep: Consumer Health Unit In Danger Of Divestiture?
Schering-Plough will retain its Consumer Health Care business in the near-term but may choose to sell the unit as it undertakes a broad restructuring plan that includes an unprecedented dividend slash to cut costs
Schering Taps Former AHP Exec Barshay To Head Consumer Health Care Unit
Schering-Plough appointed former American Home Products Senior VP Stanley Barshay as chairman of its Consumer Health Care division effective July 7